Head to head
Tirzepatide against Metformin
A dual incretin agonist against the oldest first line diabetes drug. Cost, route and effect size all differ by more than an order of magnitude in one direction or the other, and metformin carries something tirzepatide does not yet have, which is decades of population scale safety data.
Column A
TirzepatideTirzepatide (dual GIP/GLP-1 receptor agonist)
A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists.
Column B
MetforminMetformin hydrochloride (biguanide)
The most discussed drug in longevity, with enormous human safety data and a geroscience record that is consistently null. It also blunts the muscle and fitness gains from training.
Side by side, on the facts we can check
| Attribute | Tirzepatide | Metformin |
|---|---|---|
| Category | Metabolic | Longevity |
| FDA status | FDA-approved (Mounjaro for T2D and, from August 2026, to reduce major cardiovascular events in T2D; Zepbound for weight management and sleep apnea) | FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity. |
| Half-life | ~5 days | 4 to 9 hours (plasma), longer in erythrocytes |
| Molecular weight | 4,813.5 Da | 129.2 Da (165.6 Da as hydrochloride) |
| Mechanism | Simultaneously activates GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, reducing glucagon, delaying gastric emptying, and reducing appetite. The GIP component is thought to add complementary metabolic effects. | Inhibits mitochondrial complex I and activates AMPK, reducing hepatic glucose output and improving insulin sensitivity. The AMPK account is incomplete and the relative contribution of complex I inhibition, mitochondrial glycerophosphate dehydrogenase and gut-mediated effects is actively disputed between research groups. |
| Human studies cited | 4 | 3 |
| Legal status, US | FDA-approved, prescription only | Prescription only; approved for type 2 diabetes |
Frequently asked questions
What is the difference between Tirzepatide and Metformin?
Tirzepatide: A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists. Metformin: The most discussed drug in longevity, with enormous human safety data and a geroscience record that is consistently null. It also blunts the muscle and fitness gains from training.
Which has stronger research evidence, Tirzepatide or Metformin?
This database does not grade compounds. It counts what was run in people: 4 of the 4 studies cited on the Tirzepatide profile were human work, against 3 of 4 for Metformin. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Tirzepatide and Metformin FDA-approved?
Tirzepatide: FDA-approved (Mounjaro for T2D and, from August 2026, to reduce major cardiovascular events in T2D; Zepbound for weight management and sleep apnea). Metformin: FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity..
Related posts
Blog articles that cover Tirzepatide or Metformin, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
- Metabolic / Sep 8, 2026 / 9 minMariTide (Maridebart Cafraglutide): The Once-Monthly GLP-1 Agonist and GIP Blocker, Explained
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.